GlassScriptPhysician profile
Saad Bakhaya
NPI 1164510285
$4,260.67
in general payments reported to CMS, 2019-2025
12 companies · $513 in 2025
The $513 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,379 · 2020: $13.58 · 2021: $67.30 · 2022: $31.36 · 2024: $257 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $754 · Consulting Fee: $15.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $754.26 |
| Consulting Fee | $15.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $3,289.69 | 2019 | |
| Genzyme Corporation | $192.90 | 2024-2025 | |
| Ars Pharmaceuticals Operations, INC. | $181.73 | 2025 | Neffy |
| Astrazeneca Pharmaceuticals LP | $162.21 | 2025 | Airsupra |
| Glaxosmithkline, LLC. | $136.48 | 2019-2025 | Nucala, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $97.98 | 2024-2025 | |
| Genentech USA, INC. | $67.14 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $65.06 | 2019-2025 | Dupixent |
| Pharming Healthcare, INC. | $20.75 | 2025 | Ruconest |
| Amgen INC. | $16.77 | 2022 | |
| Adma Biomanufacturing LLC | $15.44 | 2025 | |
| Shire North American Group INC | $14.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saad Bakhaya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.